Disease-specific training added to a role pathway when someone joins a study in that area. Each path has
its own assessment and a self-study practice quiz bank.
Oncology
Solid tumours and haematological malignancies. RECIST 1.1, iRECIST, CTCAE v5.0 and dose-escalation
designs.
For CRAs, CTMs, data managers, PV, medical monitors, PIs and CRCs
Gastroenterology
MASH, Crohn's disease and IBS. MASLD nomenclature, endoscopic scoring and biopsy endpoints.
For CRAs, CTMs, data managers, medical monitors, PIs and CRCs
Dermatology
Plaque psoriasis, atopic dermatitis and melanoma. PASI, EASI and the HOME core outcome set.
For CRAs, CTMs, data managers, medical monitors, PIs and CRCs
Immunology and autoimmune
Rheumatology, IBD and lupus. ACR/EULAR response criteria, SLEDAI and endoscopic remission.
For CRAs, CTMs, data managers, PV, medical monitors, PIs and CRCs
Endocrinology and metabolic
Diabetes, obesity and thyroid disorders. HbA1c endpoints, hypoglycaemia adjudication and CV outcome
trials.
For CRAs, CTMs, data managers, medical monitors, PIs and CRCs
Infectious disease and AMR
Antimicrobial resistance. S/I/R terminology, MIC, EUCAST and CLSI breakpoints, and stewardship.
For CRAs, CTMs, PV, medical monitors, laboratory staff, PIs and site pharmacy
Further therapeutic areas are in development, including cardiovascular, CNS,
respiratory, rare diseases and gene and cell therapy.